In early 2006, Nabriva raised Euro 42m in a series A financing round from a group of top level international life science investors led by Nomura Phase4 Ventures. The same group of investors invested a further €15m in October 2009.
Nabriva’s current shareholders include:
• Nomura Phase4 Ventures
• HBM Partners
• The Wellcome Trust
• Global Life Science Ventures
• Novartis Venture Fund
• Sandoz
In addition, to the series A financing the company has also been awarded significant grants and loans from Austrian public institutions.
We thank the following institutions for their support:
• ZIT Zentrum für Innovation und Technologie GmbH